aspi_8k.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 17, 2026

 

ASP Isotopes Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-41555

 

87-2618235

(State or other jurisdiction of

incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

2200 Ross Avenue, Suite 4575E

Dallas, TX

 

75201

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (214) 432-8219

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.01

 

ASPI

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

 

 

 

  

Item 7.01  Regulation FD Disclosure.

 

On February 17, 2026, ASP Isotopes Inc. (the “Company”) issued a press release regarding its plans for Quantum Leap Energy LLC (“QLE”) to establish QLE’s new global corporate headquarters in Austin, Texas, which is attached hereto as Exhibit 99.1 and is incorporated by reference herein (the “Press Release”).

 

The information in this Item 7.01 and in the Press Release shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission, whether made by the Company before or after the date hereof, regardless of any general incorporation language in such filing.

 

The Press Release includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.

 

Item 9.01  Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

 

Description

99.1

 

Press Release dated February 17, 2026.

104

 

Cover Page Interactive Date File (embedded within the Inline XBRL document)

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ASP ISOTOPES INC.

 

 

 

 

Date: February 17, 2026

By:

/s/ Donald G. Ainscow

 

 

Name:

Donald G. Ainscow

 

 

Title:

Executive Vice President,

General Counsel and Secretary

 

 

 

3

 

  EXHIBIT 99.1

 

ASP Isotopes Announces Quantum Leap Energy to Establish Global Headquarters in Austin, TX

 

State’s Support of Nuclear Power and Constructive Regulatory Environment to Boost Commercial Pathway for Developer of Advanced Nuclear Fuels

 

Dallas, TX, February 17, 2026 -- ASP Isotopes Inc. (NASDAQ: ASPI) (“ASPI”) today announced its plans for Quantum Leap Energy LLC (“QLE” or the “Company”), a wholly-owned subsidiary of ASPI dedicated to advancing innovative technologies and processes across critical segments of the fission and fusion nuclear fuel cycle, to establish QLE’s new global corporate headquarters in Austin, Texas, strengthening its presence in Texas and strategically positioning the Company to better serve its United States customer base.

 

In addition to the planned global corporate headquarters, QLE intends to build a significant operational presence in Texas, with QLE’s management focused on working with Fermi America to implement the joint venture outlined in the Joint Venture Memorandum of Understanding (MOU) signed by QLE, ASPI and Fermi America last year. The collaboration contemplated by the MOU includes a joint venture between QLE and Fermi America focused on the development of a high-assay-low enriched uranium (“HALEU”) enrichment research and commercial production facility, alongside ASPI’s planned commercial facility for the production of stable isotopes and advanced nuclear materials, both to be affiliated with Fermi America’s hypergrid campus in Amarillo, Texas.

 

“As the nation’s leader in energy production, Austin and Texas have established a beacon as the natural home to America’s advanced nuclear energy industry,” said Ryno Pretorius, Chief Executive Officer of QLE. “The epicenter of the American nuclear renaissance, with its central location, affordable cost of living, highly educated workforce and supportive business climate, is a natural fit for QLE’s own headquarters. The state’s distinct pro-nuclear stance and supportive regulatory environment have proven critical to growing commercial support for the nuclear sector, and will help ensure we have access to the best talent and infrastructure in the market”

 

"Texas is home to the world’s most innovative companies, and today we are proud to welcome Quantum Leap Energy's global headquarters to our thriving business ecosystem,” said Governor Greg Abbott. “Thank you to ASPI and Quantum Leap Energy for choosing Texas for this important investment and for your growth in our state. Working together with industry leaders like Quantum Leap Energy, we will power the future of energy innovation and fuel America's nuclear resurgence from right here in Texas.”

 

QLE’s new headquarters  comes at a critical time as advanced reactor technologies are being developed globally at an accelerating pace to meet the clean, baseload power demands of AI data center infrastructure and industrial electrification. For example, the United States Department of Energy estimates that by 2035, the country will need 50 metric tons per year of HALEU to support its nuclear power industry, escalating to 500 metric tons per year by 2050.

 

About Quantum Leap Energy

 

Quantum Leap Energy is a development stage nuclear fuels company dedicated to advancing innovative technologies and processes across critical segments of the nuclear fuel cycle. The company focuses on both front-end activities, including uranium conversion, enrichment of uranium-235 for nuclear fuel production (HALEU, LEU+ and LEU), and isotopic separation of lithium-6 and lithium-7, as well as back-end radioactive waste treatment technologies. Through exclusive global rights to proprietary Aerodynamic Separation Process (ASP) and laser-based Quantum Enrichment (QE) technologies, Quantum Leap Energy aims to address gaps in the nuclear fuel supply chain for advanced nuclear reactors, small modular reactors, and fusion systems. The company has established strategic partnerships or initiatives with industry leaders including TerraPower, Fermi America, and the South Africa Nuclear Energy Corporation (Necsa) to accelerate the commercialization of critical isotopes essential for next-generation nuclear energy systems. For additional information, please visit: https://www.qleapenergy.com/.

 

 

1

 

 

About ASP Isotopes Inc.

 

ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. ASPI employs proprietary ASP technology. ASPI’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. ASPI also plans to enrich isotopes for the nuclear energy sector using QE technology that ASPI is developing. ASPI has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light isotopes).

 

Forward-Looking Statements

 

Statements contained herein relating to future plans, results, performance, expectations, achievements and the like are considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, projections about future nuclear fusion power generation technologies and enrichment methods, QLE’s anticipated growth strategies and anticipated trends in QLE’s business, statements relating to the formation of a joint venture with Fermi America, the commencement of research, development and production activities in the United States, the future of the company’s enrichment technologies as applied to uranium enrichment, the outcome of the company’s initiative to commence enrichment of uranium in South Africa and the company’s discussions with nuclear regulators in South Africa and the UK, the outcome of the project contemplated with Necsa, the expected need or desire for HALEU by third parties, the outcome of the transactions contemplated by the definitive agreements with TerraPower, commencement of supply of isotopes to customers and the application of new technology for the enrichment of isotopes, the planned construction of additional isotope enrichment facilities, and statements we make regarding expected operating results, such as future revenues and prospects from the potential commercialization of isotopes, future performance under contracts, and our strategies for product development, engaging with potential customers, market position, and financial results. These forward-looking statements involve known and unknown risks, uncertainties, and other factors, many of which may be beyond ASPI’s or QLE’s control, that may cause actual results to differ materially from any future results, performance or achievements expressed or implied by any forward-looking statements.  All forward-looking statements speak only as of the date hereof. QLE and ASPI undertake no obligation to revise or update any forward-looking statements except as may be required by applicable law.

 

Contact

[email protected]

 

 

2